Recent Updates
Recently added Catalysts
CVS Positive Sentiment

CVS Health Announces Board Changes

Key Takeaway: CVS Health has announced the appointment of Teresa Heitsenrether to its Board of Directors, effective November 18, 2026. Heitsenrether brings nearly forty years of experience in financial services and technology. Larry Robbins, who served on the Board since 2024, has departed, with his contributions acknowledged by CVS leadership.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of Teresa Heitsenrether adds valuable expertise.
  • Heitsenrether's background in data and technology aligns with CVS's goals.
  • Larry Robbins' contributions recognized during his tenure.

Full Press Release Details

• Teresa Heitsenrether to join the Board, bringing more than forty years of operating experience across data, analytics and technology at one of the world's largest financial institutions
• Larry Robbins to depart the Board after two years at CVS Health
WOONSOCKET, R.I., Aug. 17, 2026 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced the appointment of Teresa Heitsenrether to its Board of Directors and departure of Larry Robbins from its Board.
Ms. Heitsenrether joins the CVS Health Board with nearly forty years of financial services leadership experience. She currently serves as Chief Data & Analytics Officer at JPMorgan Chase & Co. and is a member of the firm's Operating Committee. Ms. Heitsenrether will join the Board of Directors effective November 18, 2026.
"Teresa's extensive experience leading complex global businesses and driving technology-enabled transformation will be invaluable as CVS Health continues to innovate on its path to become a consumer focused, health technology company," said David Joyner, Chair and Chief Executive Officer of CVS Health. "We look forward to benefiting from her deep knowledge in data, analytics, artificial intelligence, operational transformation and decades of financial expertise."
"I am excited to join the most trusted healthcare company in the country, and look forward to assisting management as they progress to the next phase in the company's strategic journey," said Teresa Heitsenrether.
A member of the Board since 2024, Mr. Robbins has served on the Audit and Public Policy and External Affairs Committees. His departure from the Board of Directors was effective on August 13, 2026.
"Larry joined our Board at a pivotal moment in CVS's history and was instrumental in helping sharpen our financial and operational focus during this period of transition for the business. From day one, he has been an invaluable and collaborative member of the Board bringing a focused financial perspective and deep knowledge of the health care industry" said David Joyner, Chair and Chief Executive Officer of CVS Health. "We are grateful for Larry's insights and commitment to help strengthen CVS over the course of these important two years, as we laid our foundation for future success."
"Two years ago we approached CVS Health Board and Management with a proposal to refresh corporate governance, improve operating performance and restore financial flexibility and discipline," said Larry Robbins, CEO of Glenview. "The goal was and has always remained to drive better outcomes for CVS customers, stronger opportunities for CVS associates and the restoration of value for CVS lenders and shareholders. We were honored to partner with the Board in a process of constructive evolution that has led to a cultural renaissance at the Company, significantly improved customer experience, a commitment to technology and innovation, a fully repaired balance sheet, dramatically improved financial performance and the recruitment and elevation of many talented leaders to form the leadership group of a revitalized CVS Health."
About Teresa Heitsenrether Teresa Heitsenrether is Executive Vice President and Chief Data & Analytics Officer of JPMorgan Chase and a member of the firm's Operating Committee. She brings nearly forty years of financial services leadership experience, with extensive expertise in data and analytics, artificial intelligence, technology-driven transformation, risk management and complex global operations. Prior to her current role, Heitsenrether held several senior leadership positions at JPMorgan Chase, including CEO of Securities Services and Global Head of Prime Brokerage & Equity Financing, where she led large-scale business transformations and international growth initiatives. She has been recognized by American Banker and Barron's among the most influential women in finance and holds an M.B.A. from New York University and a B.S. in Finance from Fordham University.
About CVS Health CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of June 30, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated 37 million people through a broad range of health insurance products and related services. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Media contact Ethan Slavin 860-273-6095 [email protected]

Investor contact Larry McGrath 800-201-0938 [email protected]

Frequently Asked Questions

Who is Teresa Heitsenrether?

Teresa Heitsenrether is the new Board member with extensive experience in financial services.

When will Teresa Heitsenrether join the Board?

She will join the CVS Health Board on November 18, 2026.

What role did Larry Robbins play at CVS Health?

Larry Robbins served on the Board and contributed to financial and operational focus.

What is CVS Health's focus moving forward?

CVS aims to innovate as a consumer-focused health technology company.

Last updated: Aug 17, 2026